These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17167280)

  • 1. Pleiotropic effects of statins in the prevention of coronary heart disease--potential side effects.
    Okuyama H; Ichikawa Y; Sun Y; Hamazaki T; Lands WE
    World Rev Nutr Diet; 2007; 96():55-66. PubMed ID: 17167280
    [No Abstract]   [Full Text] [Related]  

  • 2. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of high total cholesterol with coronary heart disease mortality differs among subject populations--familial hypercholesterolemia as a key concept.
    Okuyama H; Ichikawa Y; Sun Y; Hamazaki T; Lands WE
    World Rev Nutr Diet; 2007; 96():19-36. PubMed ID: 17167278
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of more intensive lowering of LDL cholesterol.
    Bonovas S; Nikolopoulos G; Sitaras NM
    Lancet; 2011 Feb; 377(9767):715; author reply 715-6. PubMed ID: 21353894
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Hlatky M
    J Am Coll Cardiol; 2011 Feb; 57(7):792-3. PubMed ID: 21310314
    [No Abstract]   [Full Text] [Related]  

  • 6. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 7. Towards a Paradigm Shift in Cholesterol Treatment. A Re-examination of the Cholesterol Issue in Japan.
    Hamazaki T; Okuyama H; Ogushi Y; Hama R
    Ann Nutr Metab; 2015; 66 Suppl 4():1-116. PubMed ID: 25925499
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
    J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
    MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
    Kerst LL; Mauro VF
    Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
    Poli A; Menotti A
    G Ital Cardiol; 1999 Oct; 29(10):1123-30. PubMed ID: 10546121
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comment from tHE cardiologic-angiologic viewpoint].
    Rosemann A
    Praxis (Bern 1994); 2011 Jul; 100(14):857-8. PubMed ID: 21732298
    [No Abstract]   [Full Text] [Related]  

  • 15. Statins for high-risk patients without heart disease or high cholesterol.
    Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
    Brown WV
    J Am Osteopath Assoc; 2001 Sep; 101(9 Suppl):S6-11. PubMed ID: 11575043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention and treatment of coronary heart disease. The importance of cholesterol synthesis enzyme inhibition].
    Kostner K
    Pharm Unserer Zeit; 2003; 32(6):480-7. PubMed ID: 14639829
    [No Abstract]   [Full Text] [Related]  

  • 18. Statin therapy in primary prevention: new insights regarding women and the elderly.
    Harrington C; Horne A; Hasan RK; Blumenthal RS
    Am J Cardiol; 2010 Nov; 106(9):1357-9. PubMed ID: 21029838
    [No Abstract]   [Full Text] [Related]  

  • 19. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M
    MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical trials of cholesterol lowering for the secondary prevention of coronary heart disease].
    Koizumi J
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():252-6. PubMed ID: 17821900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.